EA201170374A1 - Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний - Google Patents

Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний

Info

Publication number
EA201170374A1
EA201170374A1 EA201170374A EA201170374A EA201170374A1 EA 201170374 A1 EA201170374 A1 EA 201170374A1 EA 201170374 A EA201170374 A EA 201170374A EA 201170374 A EA201170374 A EA 201170374A EA 201170374 A1 EA201170374 A1 EA 201170374A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
autoimmune
diseases
substituted tricyclic
disease
Prior art date
Application number
EA201170374A
Other languages
English (en)
Other versions
EA036955B1 (ru
Inventor
Роберт М. Джонс
Дэниэл Дж. Бьюзард
Эндрю М. Кавасаки
Сун Хи Ким
Ларс Торесен
Юрг Леманн
Сювэнь Чжу
Original Assignee
Арена Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арена Фармасьютикалз, Инк. filed Critical Арена Фармасьютикалз, Инк.
Publication of EA201170374A1 publication Critical patent/EA201170374A1/ru
Publication of EA036955B1 publication Critical patent/EA036955B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)

Abstract

Настоящее изобретение относится к некоторым производным замещенных трициклических кислот формулы (I) и их фармацевтически приемлемым солям, которые проявляют полезные фармакологические свойства, например в качестве агонистов рецептора S1P1. Кроме того, в настоящем изобретении предложены фармацевтические композиции, содержащие соединения изобретения, а также способы применения соединений и композиций изобретения при лечении S1P1-ассоциированных нарушений, например, псориаза, ревматоидного артрита, болезни Крона, отторжения трансплантата, рассеянного склероза, системной красной волчанки, язвенного колита, диабета 1-го типа, акне, ишемического-реперфузионного повреждения миокарда, гипертонической нефропатии, гломерулосклероза, гастрита, полимиозита, тиреоидита, витилиго, гепатита, билиарного цирроза печени, микробных инфекций и ассоциированных заболеваний, вирусных инфекций и ассоциированных заболеваний, заболеваний и нарушений, опосредованных лимфоцитами, аутоиммунных заболеваний, воспалительных заболеваний и рака.
EA201170374A 2008-08-27 2009-08-26 Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний EA036955B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19031108P 2008-08-27 2008-08-27
US26951909P 2009-06-24 2009-06-24
PCT/US2009/004851 WO2010027431A1 (en) 2008-08-27 2009-08-26 Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders

Publications (2)

Publication Number Publication Date
EA201170374A1 true EA201170374A1 (ru) 2011-12-30
EA036955B1 EA036955B1 (ru) 2021-01-19

Family

ID=41491524

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170374A EA036955B1 (ru) 2008-08-27 2009-08-26 Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний

Country Status (24)

Country Link
US (3) US8415484B2 (ru)
EP (1) EP2342205B1 (ru)
JP (2) JP5726737B2 (ru)
KR (2) KR101800595B1 (ru)
CN (2) CN102197038B (ru)
AU (1) AU2009288738B9 (ru)
BR (1) BRPI0917923B1 (ru)
CA (1) CA2733671C (ru)
CY (1) CY1117830T1 (ru)
EA (1) EA036955B1 (ru)
ES (1) ES2583630T3 (ru)
HK (1) HK1158624A1 (ru)
HR (1) HRP20160890T1 (ru)
HU (1) HUE031479T2 (ru)
IL (2) IL211107A0 (ru)
MX (1) MX2011002199A (ru)
NZ (1) NZ591001A (ru)
PL (1) PL2342205T4 (ru)
PT (1) PT2342205T (ru)
RS (1) RS54970B1 (ru)
SI (1) SI2342205T1 (ru)
SM (1) SMT201600318B (ru)
WO (1) WO2010027431A1 (ru)
ZA (1) ZA201101524B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2278960T (lt) * 2008-03-17 2017-02-10 Actelion Pharmaceuticals Ltd. S1p1 receptoriaus selektyvaus agonisto dozavimo režimas
CN104311472B9 (zh) 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EA036955B1 (ru) 2008-08-27 2021-01-19 Арена Фармасьютикалз, Инк. Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
WO2011005295A1 (en) * 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CA2789480A1 (en) 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
CN104478885B (zh) * 2014-12-12 2017-08-01 常州大学 9‑氨基‑9a‑烯丙基苯并吡咯里西啶生物碱的制备方法
CN104710426B (zh) * 2014-12-12 2017-08-01 常州大学 苯并吡咯里西啶生物碱及其制备方法和用途
MX2017008925A (es) 2015-01-06 2017-10-11 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
HUE060476T2 (hu) * 2015-06-22 2023-03-28 Arena Pharm Inc (R)-2-(7-(4-ciklopentil-3-(trifluormetil)benziloxi)-1,2,3,4- tetrahidrociklopenta[B]indol-3-il)ecetsav kristályos L-arginin-sója S1P1 receptorral kapcsolatos rendellenességek esetén való alkalmazásra
US11478448B2 (en) 2017-02-16 2022-10-25 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
WO2018151873A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
WO2020051378A1 (en) 2018-09-06 2020-03-12 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
WO2020114475A1 (zh) 2018-12-06 2020-06-11 上海济煜医药科技有限公司 作为免疫调节的芳环衍生物及其制备方法和应用
WO2020140957A1 (en) * 2019-01-04 2020-07-09 Ascentage Pharma (Suzhou) Co., Ltd. Method for preparing sulfonamides drugs
CN112812052B (zh) * 2021-02-02 2023-12-01 成都阿奇生物医药科技有限公司 一种治疗溃疡性结肠炎的化合物及其制备方法和用途

Family Cites Families (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL293572A (ru) 1962-06-07
DE2226703A1 (de) 1972-05-25 1973-12-13 Schering Ag Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4810699A (en) * 1987-02-20 1989-03-07 American Home Products Corporation Substituted 1,3,4,9-tetrahydropyrano[3,4,-b]indole-1-acetic acids, pharmaceutical compositions containing them, and methods for treating inflammatory conditions and for analgesic purposes using them
US4782076A (en) * 1988-03-01 1988-11-01 American Home Products Corporation Substituted 2,3,4,9-tetrahydro-1H-carbazole-1-acetic acid derivatives, composition and use
PT95692A (pt) 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
US5221678A (en) 1990-07-26 1993-06-22 Merck Frosst Canada, Inc. (quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
US5998499A (en) 1994-03-25 1999-12-07 Dentsply G.M.B.H. Liquid crystalline (meth)acrylate compounds, composition and method
US5776967A (en) * 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
US6861448B2 (en) * 1998-01-14 2005-03-01 Virtual Drug Development, Inc. NAD synthetase inhibitors and uses thereof
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
US6410583B1 (en) * 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
WO2002039987A2 (en) 2000-11-14 2002-05-23 Neurosearch A/S Use of malaria parasite anion channel blockers for treating malaria
WO2002064616A2 (en) 2001-01-30 2002-08-22 University Of Virgina Patent Foundation Agonists and antagonists of sphingosine-1-phosphate receptors
KR100876047B1 (ko) * 2001-03-29 2008-12-26 오사까 가스 가부시키가이샤 광활성 화합물 및 감광성 수지 조성물
WO2002092068A1 (fr) 2001-05-10 2002-11-21 Ono Pharmaceutical Co., Ltd. Derives d'acide carboxylique et medicaments contenant ces derives comme principe actif
BRPI0212894B8 (pt) * 2001-09-27 2021-05-25 Kyorin Seiyaku Kk composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
CA2472715A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
JP2005516967A (ja) * 2002-01-18 2005-06-09 ザ ジェネティクス カンパニー インコーポレーティッド β−セクレターゼインヒビター
WO2003074008A2 (en) 2002-03-01 2003-09-12 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
EP1482895A4 (en) 2002-03-01 2005-04-27 Merck & Co Inc AMINO ALKYL PHOSPHONATES AND RELATED COMPOUNDS AS EDG RECEPTOR AGONISTS
CA2488117A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
AU2003252478A1 (en) * 2002-07-10 2004-02-02 Ono Pharmaceutical Co., Ltd. Ccr4 antagonist and medicinal use thereof
AU2003259296A1 (en) 2002-07-30 2004-02-16 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
EP2385032A1 (en) * 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited GPR40 Receptor function regulator
JP4516430B2 (ja) * 2002-12-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション １−（アミノ）インダン並びに（１，２−ジヒドロ−３−アミノ）−ベンゾフラン、ベンゾチオフェン及びインドール
EP1594508B1 (en) 2003-02-11 2012-08-08 Irm Llc Novel bicyclic compounds and compositions
MXPA05008760A (es) 2003-02-18 2006-03-21 Kyorin Seiyaku Kk Derivados de acido aminofosfonico, sales del mismo y moduladores del receptor sip.
MXPA05011539A (es) * 2003-04-30 2006-01-23 Inst For Pharm Discovery Inc Acidos carboxilicos sustituidos con heterociclo como inhibidores de la proteina tirosina-fosfatasa-1b.
CN1809531B (zh) * 2003-04-30 2010-05-26 诺瓦提斯公司 作为鞘氨醇-1-磷酸受体调节剂的氨基丙醇衍生物
WO2004096752A1 (en) 2003-04-30 2004-11-11 Novartis Ag Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
JP2006528980A (ja) 2003-05-15 2006-12-28 メルク　エンド　カムパニー　インコーポレーテッド Ｓ１ｐ受容体作働薬としての３−（２−アミノ−１−アザシクロ）−５−アリール−１，２，４−オキサジアゾール類
WO2004104205A2 (en) 2003-05-16 2004-12-02 Merck & Co., Inc. Enzymatic preparation of chiral indole esters
CN1791592B (zh) 2003-05-19 2012-07-04 Irm责任有限公司 免疫抑制剂化合物和组合物
CA2524048C (en) 2003-05-19 2013-06-25 Irm Llc Immunosuppressant compounds and compositions
AU2004249664A1 (en) 2003-05-19 2004-12-29 Irm Llc Immunosuppressant compounds and compositions
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
GB0313612D0 (en) * 2003-06-12 2003-07-16 Novartis Ag Organic compounds
EP1661879A4 (en) * 2003-08-04 2006-11-29 Ono Pharmaceutical Co A DIPHENYL ETHER COMPOUND, PROCESS FOR THE PRODUCTION AND USE THEREOF
ATE449069T1 (de) 2003-08-28 2009-12-15 Novartis Pharma Gmbh Aminopropanolderivate
CN101407471A (zh) * 2003-08-29 2009-04-15 小野药品工业株式会社 能够结合s1p受体的化合物及其药物用途
JPWO2005023771A1 (ja) * 2003-09-05 2006-11-02 小野薬品工業株式会社 ケモカインレセプターアンタゴニストおよびその医薬用途
CA2539438A1 (en) * 2003-10-01 2005-04-14 Merck And Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
US7638637B2 (en) 2003-11-03 2009-12-29 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
JPWO2005044780A1 (ja) 2003-11-10 2007-05-17 杏林製薬株式会社 アミノカルボン酸誘導体とその付加塩及びｓ１ｐ受容体調節剤
AU2004299456B2 (en) 2003-12-17 2010-10-07 Merck Sharp & Dohme Corp. (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
JP4766384B2 (ja) * 2003-12-19 2011-09-07 小野薬品工業株式会社 リゾホスファチジン酸受容体拮抗作用を有する化合物およびその用途
GB0401332D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
EP1733724A4 (en) 2004-02-24 2010-07-07 Sankyo Co Aminoalcohol compound
AU2005217641B2 (en) 2004-02-24 2008-02-14 Irm Llc Immunosuppressant compounds and compositions
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
EP1726585A4 (en) * 2004-03-05 2009-07-15 Banyu Pharma Co Ltd HETEROCYCLIC DERIVATIVE WITH FIVE ELEMENTS SUBSTITUTED BY A DIARYLE
GB0405289D0 (en) 2004-03-09 2004-04-21 Novartis Ag Organic compounds
ES2297695T3 (es) 2004-04-02 2008-05-01 MERCK & CO., INC. Procedimiento de hidrogeneracion asimetrica util para la preparacion de derivados de cicloalcanoindol.
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
EP1760071A4 (en) * 2004-06-23 2008-03-05 Ono Pharmaceutical Co COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF
PT1772145E (pt) 2004-07-16 2011-05-27 Kyorin Seiyaku Kk Processo de utiliza??o eficaz de um medicamento e processo respeitante ? preven??o de efeitos secund?rios
JP2007284350A (ja) * 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
TW200611687A (en) 2004-07-29 2006-04-16 Sankyo Co Pharmaceutical compositions used for immunosuppressant
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
RU2383536C2 (ru) 2004-08-04 2010-03-10 Тайсо Фармасьютикал Ко., Лтд. Производное триазола
MX2007001661A (es) 2004-08-13 2007-04-23 Praecis Pharm Inc Metodos y composiciones para modular la actividad del receptor de esfingosina -1 fosfato (sip).
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
JP2008514611A (ja) 2004-09-23 2008-05-08 ワイス Ｃ型肝炎ウイルスによる感染を処置するためのカルバゾールおよびシクロペンタインドールの誘導体
US7189748B2 (en) * 2004-10-12 2007-03-13 Forbes Medi-Tech (Research), Inc. Compounds and methods for treating insulin resistance and cardiomyopathy
CN101043887A (zh) 2004-10-22 2007-09-26 默克公司 用作s1p受体激动剂的2－(芳基)氮杂环甲基羧酸酯、磺酸酯、膦酸酯、次膦酸酯和杂环化合物
PL1650186T3 (pl) 2004-10-22 2008-11-28 Bioprojet Soc Civ Nowe pochodne kwasów dikarboksylowych
CA2588766A1 (en) * 2004-11-18 2006-05-26 The Institutes For Pharmaceutical Discovery, Llc Heterocycle substituted carboxylic acids
WO2006057448A1 (ja) * 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体
US7888527B2 (en) 2004-12-06 2011-02-15 University Of Virginia Patent Foundation Aryl amide sphingosine 1-phosphate analogs
EP2592066B1 (en) 2004-12-13 2014-12-03 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medical use thereof
US7914859B2 (en) 2005-01-25 2011-03-29 Merck Patent Gmbh Mesogenic compounds, liquid crystal medium and liquid crystal display
WO2006088944A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1- phos phate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
AU2006226022A1 (en) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
KR101382733B1 (ko) 2005-03-23 2014-04-14 액테리온 파마슈티칼 리미티드 면역조절물질로서의 수첨 벤조(ｃ) 티오펜 유도체
SI1863474T1 (sl) 2005-03-23 2009-04-30 Actelion Pharmaceuticals Ltd Novi derivati tiofena kot agonisti receptorja sfingozin-1-fosfat-1
US20080306124A1 (en) 2005-06-08 2008-12-11 Rainer Albert Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands
AU2006260573A1 (en) 2005-06-24 2006-12-28 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives
TWI418350B (zh) * 2005-06-24 2013-12-11 Sankyo Co 含有ｐｐａｒ調節劑之醫藥組成物的用途
US20070060573A1 (en) * 2005-08-10 2007-03-15 Lars Wortmann Acyltryptophanols
AU2006283175A1 (en) 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
JPWO2007037196A1 (ja) 2005-09-29 2009-04-09 山本化成株式会社 インドリン系化合物及びその製造方法
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
AU2006317689B2 (en) 2005-11-23 2013-07-25 Epix Delaware, Inc. S1P receptor modulating compounds and use thereof
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
TW200736234A (en) 2006-01-17 2007-10-01 Astrazeneca Ab Chemical compounds
DE602007003074D1 (de) 2006-01-24 2009-12-17 Actelion Pharmaceuticals Ltd Neue pyrinderivate
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
TW200806611A (en) 2006-02-09 2008-02-01 Daiichi Seiyaku Co Novel amidopropionic acid derivatives and medicine containing the same
JP2009526073A (ja) 2006-02-09 2009-07-16 ユニバーシティ オブ バージニア パテント ファンデーション 二環式スフィンゴシン−１−リン酸受容体アナログ
US20070191371A1 (en) * 2006-02-14 2007-08-16 Kalypsys, Inc. Heterocyclic modulators of ppar
CN101460458A (zh) * 2006-02-15 2009-06-17 阿勒根公司 具有1－磷酸－鞘氨醇(s1p)受体拮抗剂生物活性的带芳基或者杂芳基基团的吲哚－3－羧酸的酰胺、酯、硫代酰胺和硫羟酸酯化合物
WO2007095561A2 (en) 2006-02-15 2007-08-23 Allergan, Inc. Indole-3-carboxylic acid amide, ester, thioamide and thiol ester compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
CN101384566A (zh) 2006-02-21 2009-03-11 弗吉尼亚大学专利基金会 作为s1p受体激动剂的苯基-环烷基和苯基-杂环衍生物
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
JP2009530281A (ja) * 2006-03-14 2009-08-27 アムジエン・インコーポレーテツド 代謝障害の治療に有用である二環式カルボン酸誘導体
WO2007109334A2 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. Sip receptor modulating compounds and use thereof
AU2007227274A1 (en) 2006-03-21 2007-09-27 Epix Delaware, Inc. S1P receptor modulating compounds
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
WO2007116866A1 (ja) * 2006-04-03 2007-10-18 Astellas Pharma Inc. ヘテロ化合物
GB0607389D0 (en) 2006-04-12 2006-05-24 Novartis Ag Organic compounds
JPWO2007129745A1 (ja) 2006-05-09 2009-09-17 第一三共株式会社 ヘテロアリールアミド低級カルボン酸誘導体
WO2007129473A1 (ja) 2006-05-09 2007-11-15 Daiichi Sankyo Company, Limited 二環性アリール誘導体
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
TW200823182A (en) 2006-08-01 2008-06-01 Praecis Pharm Inc Chemical compounds
WO2008016674A1 (en) 2006-08-01 2008-02-07 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine- 1- phosphate receptor (slp)
US20090318389A1 (en) 2006-08-04 2009-12-24 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine-1 phosphate receptor
WO2008018427A1 (fr) 2006-08-08 2008-02-14 Kyorin Pharmaceutical Co., Ltd. Dérivé d'ester de l'acide aminophosphorique et modulateur du récepteur s1p contenant ledit dérivé en tant que principe actif
US20110039933A1 (en) 2006-08-24 2011-02-17 Praecis Pharmaceuticals Incorporation S1p-1 receptor agonists
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
TWI392671B (zh) 2006-09-07 2013-04-11 Actelion Pharmaceuticals Ltd 吡啶-４-基衍生物
CA2662852A1 (en) 2006-09-07 2008-03-13 Allergan, Inc. Heteroaromatic compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity
MX2009002558A (es) 2006-09-08 2009-03-20 Novartis Ag Derivados de n-biaril-(hetero)-aril-sulfonamida utiles en el tratamiento de enfermedades mediadas por las interacciones de los linfocitos.
AU2007298593A1 (en) 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
MX2009006304A (es) 2006-12-15 2009-06-23 Abbott Lab Nuevos compuestos de oxadiazol.
EP2120575A4 (en) 2006-12-21 2011-04-27 Abbott Lab AGONISTS AND ANTAGONISTS OF SPHINGOSINE-1-PHOSPHATE RECEPTORS
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
EP2125723A1 (en) 2007-01-11 2009-12-02 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (s1p) receptor antagonist biological activity
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
WO2008097819A2 (en) 2007-02-05 2008-08-14 Smithkline Beecham Corporation Chemical compounds
MX2009009597A (es) 2007-03-16 2009-09-16 Actelion Pharmaceuticals Ltd Derivados de amino-piridina como agonistas del receptor s1p1/edg1.
WO2008128951A1 (en) 2007-04-19 2008-10-30 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
EP2014653A1 (en) 2007-06-15 2009-01-14 Bioprojet Novel dicarboxylic acid derivatives as S1P1 receptor agonists
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
WO2009019506A1 (en) 2007-08-03 2009-02-12 Astrazeneca Ab Heterocyclyc sulfonamides having edg-1 antagonistic activity
AU2008285722B2 (en) 2007-08-08 2013-06-20 Merck Serono S.A. 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (S1P) receptor for the treatment of multiple sclerosis
UY31468A1 (es) 2007-11-15 2009-07-17 Derivados bis-(sulfonilamino) en terapia 065
JP2011506600A (ja) 2007-12-18 2011-03-03 アリーナ ファーマシューティカルズ， インコーポレイテッド 自己免疫性障害および炎症性障害の治療において有用なテトラヒドロシクロペンタ［ｂ］インドール−３−イルカルボン酸誘導体
EP2252615A1 (en) 2008-01-25 2010-11-24 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a]indol-1-yl carboxylic derivatives which act as s1p1 agonists
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
EA021672B1 (ru) 2008-05-14 2015-08-31 Дзе Скриппс Рисёч Инститьют Модуляторы рецепторов сфингозин-1-фосфата и их применение
WO2009151621A1 (en) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en) 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
CN104311472B9 (zh) 2008-07-23 2020-03-17 艾尼纳制药公司 经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
EA036955B1 (ru) * 2008-08-27 2021-01-19 Арена Фармасьютикалз, Инк. Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
WO2010093704A1 (en) 2009-02-10 2010-08-19 Abbott Laboratories Agonists and antagonists of the s1p5 receptor, and methods of uses thereof
WO2011005290A1 (en) 2009-06-23 2011-01-13 Arena Pharmaceuticals, Inc. Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders
WO2011005295A1 (en) 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
MX336881B (es) 2009-10-29 2016-02-04 Bristol Myers Squibb Co Compuestos heterociclicos triciclicos.
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CA2789480A1 (en) * 2010-03-03 2011-09-09 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
JP2013533286A (ja) 2010-07-30 2013-08-22 セントルイス ユニバーシティ 疼痛を治療する方法

Also Published As

Publication number Publication date
US20130184307A1 (en) 2013-07-18
CN102197038A (zh) 2011-09-21
EP2342205B1 (en) 2016-04-20
CN105816453A (zh) 2016-08-03
EP2342205A1 (en) 2011-07-13
WO2010027431A1 (en) 2010-03-11
KR20170063992A (ko) 2017-06-08
US20110160243A1 (en) 2011-06-30
PL2342205T3 (pl) 2016-12-30
IL211107A0 (en) 2011-04-28
ES2583630T3 (es) 2016-09-21
CY1117830T1 (el) 2017-05-17
KR101800595B1 (ko) 2017-11-22
BRPI0917923A2 (pt) 2019-09-10
AU2009288738A1 (en) 2010-03-11
CN102197038B (zh) 2016-04-20
IL233869A0 (en) 2014-09-30
CA2733671A1 (en) 2010-03-11
US8415484B2 (en) 2013-04-09
KR20110058849A (ko) 2011-06-01
HUE031479T2 (en) 2017-07-28
MX2011002199A (es) 2011-05-10
ZA201101524B (en) 2012-07-25
AU2009288738B2 (en) 2015-04-09
IL233869A (en) 2015-05-31
PT2342205T (pt) 2016-07-28
JP2012501327A (ja) 2012-01-19
BRPI0917923B1 (pt) 2022-04-05
JP5726737B2 (ja) 2015-06-03
JP2015110641A (ja) 2015-06-18
PL2342205T4 (pl) 2016-12-30
RS54970B1 (sr) 2016-11-30
CN105816453B (zh) 2021-03-05
EA036955B1 (ru) 2021-01-19
HK1158624A1 (zh) 2012-07-20
SMT201600318B (it) 2016-11-10
US20150336966A1 (en) 2015-11-26
NZ591001A (en) 2012-11-30
SI2342205T1 (sl) 2016-09-30
CA2733671C (en) 2018-01-02
US9108969B2 (en) 2015-08-18
AU2009288738B9 (en) 2015-04-16
HRP20160890T1 (hr) 2016-09-23

Similar Documents

Publication Publication Date Title
EA201170374A1 (ru) Производные замещенных трициклических кислот в качестве агонистов рецептора s1p1, применимые при лечении аутоиммунных и воспалительных заболеваний
EA201170251A1 (ru) ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ АУТОИММУННЫХ И ВОСПАЛИТЕЛЬНЫХ РАССТРОЙСТВ
ATE531711T1 (de) Für die behandlung von autoimmunerkrankungen und entzündlichen erkrankungen geeignete tetrahydrocyclopentaäbüindol-3- ylcarbonsäurederivate
WO2011005295A8 (en) Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
PH12014502524B1 (en) Carboxylic acid compounds
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
UY31986A (es) Derivados n- sustituídos de la 2-metil-propionamida;{1-[5-sustiuido-4-sustituido-tiazol-2-il-carbamoil]-1-metil-etil} amidas de ácidos carboxílicos sustituidos, derivados farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
RU2009135621A (ru) Хинолиновые производные для лечения воспалительных заболеваний
EA201070929A1 (ru) ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ
TN2009000524A1 (en) Novel dicarboxylic acid derivatives as s1p1 receptor agonists
EA201391158A1 (ru) Диаминиевые соли фенотиазина и их применение
MX2012004020A (es) Analogos de heterociclilo pirazolopirimidina como inhibidores de jak.
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
AR057770A1 (es) Inhibidores de la p38-map-quinasa y composicion farmaceutica
EA201100503A1 (ru) Глюкозидные производные и их применения
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
CA2769553A1 (en) Novel pyrimidine and triazine hepcidin antagonists
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
EA201071329A1 (ru) Диамидные производные адамантана и их применение
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
EA201200602A1 (ru) Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1
BR112015007503A2 (pt) derivados de oxazolina terapeuticamente ativos
HRP20100726T1 (hr) Triciklički spojevi i njihova upotreba kao modulatora glukokortikoidnih receptora

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM